Testing effectiveness (Phase 2)Not Yet RecruitingNCT07819838
What this trial is testing
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
Who this might be right for
Recurrent Childhood Malignant Solid NeoplasmRecurrent Childhood NeuroblastomaRecurrent Childhood Rhabdomyosarcoma+3 more
Children's Oncology Group 77